Polymorphism of the N-acetyltransferase (NAT2), smoking and the potential risk of periodontal disease

被引:26
|
作者
Meisel, P
Timm, R
Sawaf, H
Fanghänel, J
Siegmund, W
Kocher, T
机构
[1] Ernst Moritz Arndt Univ Greifswald, Dept Pharmacol, D-17487 Greifswald, Germany
[2] Ernst Moritz Arndt Univ Greifswald, Dept Periodont, D-17487 Greifswald, Germany
关键词
arylamine N-acetyltransferase; smoking; periodontal disease; polymorphism;
D O I
10.1007/s002040000136
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Periodontal disease is a common multifactorial process that leads to bone destruction and tooth loss. Interactions of environmental and genetic factors determine the extent and severity of periodontal disease. Smoking is one of the risk factors for periodontal disease, and the risk may be influenced by the polymorphism of N-acetyltransferase (NAT2) via metabolism of smoke-derived xenobiotics. We therefore hypothesized that a NAT2 genotype would be a risk factor for periodontal disease. A total of 154 Caucasian subjects were assigned to one of two groups (1) no or mild and (2) severe periodontal disease based on radiographic (bone destruction) and clinical criteria (probing depth, attachment loss) and the number of teeth. In all subjects genotyping for mutations on NAT2 was performed by means of PCR and RFLP analysis. In the less-affected group genotyping showed a fraction of predicted slow and rapid acetylators (53.6% and 46.4%, respectively) corresponding to the normal distribution in Caucasians. Severely affected patients were predominantly slow acetylators, the odds ratios being between 2.38 and 5.02 for the NAT2-related risk depending on the outcome parameters chosen. Adjustment for age had no influence on these findings. Our data indicate that the slow acetylator phenotype is associated with a higher risk of periodontitis, especially with respect to the severity of the disease. Possible implications with respect to the risk associated with smoking are discussed.
引用
收藏
页码:343 / 348
页数:6
相关论文
共 50 条
  • [1] Association between bone loss in periodontal disease and polymorphism of N-acetyltransferase (NAT2)
    Kocher, T
    Sawaf, H
    Fanghänel, J
    Timm, R
    Meisel, P
    JOURNAL OF CLINICAL PERIODONTOLOGY, 2002, 29 (01) : 21 - 27
  • [2] N-Acetyltransferase 2 (NAT2) Polymorphism in Patients with Atopic Asthma
    Pawlik, Andrzej
    Juzyszyn, Zygmunt
    Gawronska-Szklarz, Barbara
    ARCHIVES OF MEDICAL RESEARCH, 2009, 40 (04) : 264 - 267
  • [3] N-Acetyltransferase 2 (NAT2) gene polymorphism and exposure to smoking in lung cancer of Chinese males
    Fangshuo Tian
    Yue Zhang
    Yangwu Ren
    Li Shen
    Wei Wu
    Baosen Zhou
    Medical Oncology, 2014, 31
  • [4] N-Acetyltransferase 2 (NAT2) gene polymorphism and exposure to smoking in lung cancer of Chinese males
    Tian, Fangshuo
    Zhang, Yue
    Ren, Yangwu
    Shen, Li
    Wu, Wei
    Zhou, Baosen
    MEDICAL ONCOLOGY, 2014, 31 (08)
  • [5] N-acetyltransferase 2 (Nat2) polymorphism in the sand rat Psammomys obesus
    Khelil, Malika
    Djerdjouri, Bahia
    Tayebi, Bouchentouf
    TOXICOLOGY MECHANISMS AND METHODS, 2010, 20 (08): : 440 - 444
  • [6] N-Acetyltransferase 2 (NAT2) polymorphism as a risk modifier of susceptibility to pediatric acute lymphoblastic leukemia
    Kamel, Azza M.
    Ebid, Gamal T. A.
    Moussa, Heba S.
    TUMOR BIOLOGY, 2015, 36 (08) : 6341 - 6348
  • [7] Active cigarette smoking and the risk of breast cancer at the level of N-acetyltransferase 2 (NAT2) gene polymorphisms
    Kasajova, Petra
    Holubekova, Veronika
    Mendelova, Andrea
    Lasabova, Zora
    Zubor, Pavol
    Kudela, Erik
    Biskupska-Bodova, Kristina
    Danko, Jan
    TUMOR BIOLOGY, 2016, 37 (06) : 7929 - 7937
  • [8] Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis
    K. Skrętkowicz
    J. Skrętkowicz
    B. Gawrońska-Szklarz
    W. Górnik
    M. Rychlik-Sych
    A. Sysa-Jędrzejowska
    European Journal of Clinical Pharmacology, 2005, 60 : 773 - 778
  • [9] Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic sclerosis
    Skretkowicz, K
    Skretkowicz, J
    Gawronska-Szklarz, B
    Górnik, W
    Rychlik-Sych, M
    Sysa-Jedrzejowska, A
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 60 (11) : 773 - 778
  • [10] N-acetyltransferase (NAT2) genotype and susceptibility to sporadic Alzheimer's disease
    Rocha, L
    Garcia, C
    de Mendonça, A
    Gil, JP
    Bishop, DT
    Lechner, MC
    PHARMACOGENETICS, 1999, 9 (01): : 9 - 15